ASRT: 25-NSE · delisting
Form 25-NSE was filed, notifying the SEC of the removal of Assertio Holdings, Inc. from listing and registration on a national securities exchange. This form indicates that the company's securities will no longer be traded on the exchange. The filing of Form 25-NSE typically follows a failure to meet continued listing standards or a voluntary decision to delist, resulting in a significant reduction in liquidity for shareholders.
ASRT: 15-12G · delisting
Assertio Holdings, Inc. has filed a Form 15 to certify the termination of its registration under Section 12(g) of the Securities Exchange Act of 1934. This filing suspends the company's duty to file periodic reports, such as 10-K and 10-Q forms, with the SEC. The company is eligible to suspend reporting because it has fewer than 300 holders of record. As of the certification date, Assertio reported having exactly one holder of record, indicating the stock is no longer widely held or publicly traded in any meaningful capacity. The notice, signed by Treasurer Ravi Yadavar, signifies that Assertio will cease providing public financial disclosures and regulatory updates, effectively transitioning to a private or non-reporting status.
ASRT: 8-K · acquisition merger
Assertio Holdings announced the completion of its merger with Zydus Worldwide DMCC, with Zydus acquiring all outstanding shares for $23.50 per share in cash. Following the tender offer where approximately 66.32% of shares were tendered, the merger was consummated on June 16, 2026, making Assertio a wholly owned subsidiary. As a result of the merger, the company requested that its shares be halted and delisted from the Nasdaq Capital Market effective immediately. The company intends to file a Form 15 to suspend its reporting obligations under the Securities Exchange Act. The Board of Directors underwent a complete change, with Ravi Yadavar and Punit Patel becoming the new directors while all prior directors resigned. Additionally, the company entered into a First Supplemental Indenture to address the Fundamental Change regarding its $40 million aggregate principal amount of 6.50% Convertible Senior Notes due 2027.
Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027
Assertio completed its merger with Zydus Lifesciences, resulting in the immediate delisting of ASRT common stock from the Nasdaq. Stockholders will receive $23.50 per share in cash, while the company issued a fundamental change notice regarding its outstanding 6.50% Convertible Senior Notes due 2027. Noteholders may elect to repurchase their notes for 100% of principal plus accrued interest or convert them for cash consideration of approximately $382.58 per $1,000 principal.
ASRT: SC 14D9/A · acquisition merger
Assertio Holdings announced that the tender offer by Zydus Worldwide DMCC to acquire all outstanding shares expired on June 15, 2026, with shareholders tendering approximately 66.32% of the company's common stock. The level of acceptance satisfied the minimum condition required under the merger agreement, allowing the purchaser to proceed with the acquisition under Section 251(h) of the Delaware General Corporation Law without a formal stockholder vote. The merger is expected to close on June 16, 2026, at which point Assertio will become a wholly owned subsidiary of Zydus and its shares will be delisted from the Nasdaq Capital Market, ceasing all public trading.
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC issued a shareholder-solicitation notice naming ASRT, SUNE, RLYB, and TMHC; no new disclosure from the companies themselves. The release is a routine lead-plaintiff-deadline reminder soliciting investors with losses to contact the firm on a contingency basis. This is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.
Are SILA, UNF, ASRT, KW Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC issued a shareholder-solicitation notice naming Assertio Holdings (ASRT) alongside three other companies. The firm is investigating potential securities law violations and breaches of fiduciary duty related to Assertio's sale to Garda Therapeutics for $18.00 per share in cash and a contingent value right. This is a routine law-firm marketing release soliciting investors with losses to contact the firm on a contingency basis; it contains no new disclosure from the issuer.
Assertio Holdings, Inc. (ASRT) announced on May 18, 2026, that it has entered into a definitive agreement to be acquired by Zydus Worldwide DMCC. The transaction involves a cash tender offer for all outstanding shares of common stock at a price of $23.50 per share. The tender offer commenced on May 18, 2026, and will be followed by a merger in which Assertio will become a wholly-owned subsidiary of Zydus. This deal represents a significant change of control for the company, with the acquirer being a UAE-based entity and its Delaware subsidiary acting as the purchaser. The agreement also addresses the company's 6.50% Convertible Senior Notes due 2027, constituting a 'Fundamental Change' under the indenture. Holders of these notes will have the right to require repurchase at 100% of principal plus accrued interest or convert at an increased rate, although the initial requirement to make a concurrent note offer was waived by the parent company on the filing date.
Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash
Assertio and Garda Mutually Agree to Delay Launch of Tender Offer
Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer
Assertio and acquirer Garda Therapeutics mutually agreed to postpone the commencement of the tender offer to May 8, 2026. The $153.2 million acquisition at $21.80 per share remains unchanged, with the Schedule 14D-9 filing also expected on May 8. The tender offer for Convertible Senior Notes is similarly delayed until next week.
Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last?
Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics
Assertio accepted an amended merger agreement with Garda Therapeutics, increasing the all-cash offer by 21.1% to $21.80 per share for a total deal value of $153.2 million. The revised offer, which represents a 63.1% premium to the unaffected stock price, follows a competitive review process and comes with fully committed equity and debt financing. In connection with the transaction, Assertio withdrew its 2026 guidance and cancelled its first quarter earnings conference call.
Are Medical Stocks Lagging Assertio (ASRT) This Year?
Assertio and Garda Mutually Agree to Extend Tender Offer Deadline
Assertio and Garda Therapeutics mutually agreed to extend the deadline to commence the tender offer to May 4, 2026. The acquisition terms remain unchanged at $18.00 per share in cash, representing a total cash consideration of $125.1 million plus a contingent value right. This extension falls within the 20-day window-shop period, allowing Assertio to continue soliciting alternative proposals that could provide superior value.
Assertio Provides Update on Garda Therapeutics Tender Process
Assertio announced that Garda Therapeutics intends to commence its tender offer to acquire all outstanding shares on April 29, 2026, immediately after the 20-day window-shop period expires. The definitive agreement, signed April 8, stipulates a purchase price of $18.00 per share in cash for total consideration of $125.1 million, plus a contingent value right. Assertio is permitted to solicit superior proposals during the window-shop period, though a reduced breakup fee would apply if the board terminates the Garda Agreement in favor of a superior bid.
Does Assertio (ASRT) Have the Potential to Rally 115.05% as Wall Street Analysts Expect?
